Loading...
XSTOACTI
Market cap10mUSD
Dec 23, Last price  
0.11SEK
1D
-3.40%
1Q
-64.94%
Jan 2017
-98.63%
Name

Active Biotech AB publ

Chart & Performance

D1W1MN
XSTO:ACTI chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.74%
Rev. gr., 5y
-11.87%
Revenues
0k
69,724,0009,152,00066,359,00012,077,00053,456,00010,772,00011,356,000234,593,000219,092,000108,145,0002,265,00016,275,00019,042,00020,246,00020,051,0008,425,0006,725,000000
Net income
-46m
L-21.96%
-174,228,000-135,415,000-139,180,000-207,718,000-181,586,000-223,977,000-221,065,000-94,550,000-175,015,000-212,086,000-231,512,000-193,531,000-59,584,000-108,793,000-36,878,000-36,066,000-32,117,000-49,883,000-58,691,000-45,800,000
CFO
-46m
L-16.61%
-149,645,000-192,510,000-100,133,000-186,704,000-159,463,000-224,772,000-196,320,000-46,971,000-240,396,000-102,250,000-267,090,000-217,887,000-73,163,000-46,447,000-40,647,000-35,813,000-32,216,000-46,166,000-54,850,000-45,741,000
Earnings
Feb 13, 2025

Profile

Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
URL
https://www.activebiotech.com/
IPO date
Dec 01, 1986
Employees
8
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
48,159
59,380
51,062
Unusual Expense (Income)
NOPBT
(48,159)
(59,380)
(51,062)
NOPBT Margin
Operating Taxes
319
58
Tax Rate
NOPAT
(48,159)
(59,699)
(51,120)
Net income
(45,800)
-21.96%
(58,691)
17.66%
(49,883)
55.32%
Dividends
Dividend yield
Proceeds from repurchase of equity
43,468
46,832
76,249
BB yield
-35.07%
-18.72%
-24.56%
Debt
Debt current
1,545
1,606
760
Long-term debt
7,545
10,470
1,212
Deferred revenue
Other long-term liabilities
Net debt
(27,128)
(30,096)
(51,163)
Cash flow
Cash from operating activities
(45,741)
(54,850)
(46,166)
CAPEX
(245)
Cash from investing activities
(245)
Cash from financing activities
40,163
43,757
73,087
FCF
(46,611)
(65,018)
(50,195)
Balance
Cash
36,218
41,796
53,134
Long term investments
376
1,000
Excess cash
36,218
42,172
53,135
Stockholders' equity
(3,441,490)
(3,396,361)
(3,338,921)
Invested Capital
3,476,702
3,436,674
3,386,326
ROIC
ROCE
EV
Common stock shares outstanding
271,524
260,038
245,657
Price
0.46
-52.55%
0.96
-23.89%
1.26
-33.12%
Market cap
123,951
-50.45%
250,156
-19.44%
310,511
-2.42%
EV
96,823
220,060
259,348
EBITDA
(46,484)
(57,885)
(49,784)
EV/EBITDA
Interest
206
26
Interest/NOPBT